Rapid Response Grants

Rapid Response Grants is sponsored by The Lilly and Blair Foundation. These grants support urgent, time-sensitive opportunities and bridge critical funding gaps for research toward treatment and clinical trial readiness for childhood-onset de novo SPG4. Highest priority areas include AAV9 gene therapy, ASO development, drug repurposing, combination therapies, and preclinical safety and efficacy studies.

Rapid Response Grants — The Lilly and Blair Foundation | Grantable The Lilly and Blair Foundation Foundation Rolling (Quarterly) Grants for Science Research Overview: Designed to support urgent, time-sensitive opportunities and bridge critical funding gaps for childhood-onset SPG4 research.

Funder: The Lilly and Blair Foundation (VA, US) Geographic Scope: International eligible (academic or nonprofit research institutions, research hospitals, and international institutions) Funding Duration: 6-month projects Decision Timeline: ~4-week turnaround Contact: info@lillyandblair.

org Highest Priority: Therapeutic Development Drug repurposing with clear clinical pathways Preclinical safety and efficacy studies High Priority: Clinical Trial Enablers Biomarker development (e.g., NULISA) Natural history expansion Outcome measure validation Patient-derived models for drug screening Tools accelerating therapeutic development Foundational Research (When Translationally Relevant) Mechanism studies tied to therapeutic development Identification of druggable targets Work informing gene therapy or ASO design Studies supporting regulatory readiness Eligibility and Requirements Principal Investigators at academic or nonprofit research institutions Research hospitals and international institutions For-profit entities (if research is non-proprietary and publishable) Each PI may submit only one proposal per program per cycle Previous awardees are eligible to apply for continuation funding Postdoctoral researchers may be included as key personnel but cannot serve as Principal Investigators Research must address SPG4 No overlap with existing funding Institutional approval required All prior reporting obligations must be complete Submission: Rolling applications (ongoing) Review Process: Internal review by Foundation leadership; evaluated on urgency, feasibility, and impact Project Start: Flexible start dates Grant funds support direct research costs Indirect costs may be included only if required by submitting institution, capped at 10% of total direct costs Equipment purchases over $5,000 require prior approval Submission Method: Email all materials as a single PDF to info@lillyandblair.

org Rapid Response – [PI Last Name] – [Institution] 2. Project Narrative (Lay Summary) 3. Mutation Relevance Statement 4.

Research Strategy (Specific Aims, Approach, Timeline) 6. Budget and Justification 7. Biosketches (PI + Key Personnel) 8.

Facilities and Resources 9. Current and Pending Support 10. IRB/IACUC Documentation (if applicable) 11.

Letters of Support (optional) 12.

Co-Funding Documentation (if applicable) Format: Single PDF file (≤20MB) Page limits strictly enforced Apply with Grantable Learn more Focus Areas & Funding Uses Browse similar grants by category Grants for Science Research Similar grants from this funder and related organizations Nemaline Myopathy Research Grants (RFA) Up to $100,000 per year for up to three years (up to five grants available) WAM Research Grant Program Paul E.

Strandjord Young Investigator Grant Jonas Environmental Health Education Project Michelson Prizes: Next Generation Grants British Mycological Society Ready to apply for Rapid Response Grants? Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster. Apply with Grantable Learn more